Home>
US Stocks>
Redhill Biopharma-sp Adr Share Price

Redhill Biopharma-sp Adr share price today

(RDHL)

Redhill Biopharma-sp Adr share price is $5.64 & ₹488.47 as on 18 Jan 2025, 2.30 'hrs' IST

$5.64

▲

-0.06

(-0.99%)

Market is closed - opens 8 PM, 21 Jan 2025

View live Redhill Biopharma-sp Adr share price in Dollar and Rupees. Guide to invest in Redhill Biopharma-sp Adr stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Redhill Biopharma-sp Adr, along with analyst recommendations, forecasts, and comprehensive financials.

Redhill Biopharma-sp Adr share price movements

Today's Low: $5.61
Today's High: $5.83
$5.64
0.53%
Downside
Day's Volatility :3.77%
Upside
3.26%
52 Weeks Low: $5.41
52 Weeks High: $31.50
$5.64
4.08%
Downside
52 Weeks Volatility :82.83%
Upside
82.1%

Redhill Biopharma-sp Adr Returns

Period	Redhill Biopharma Ltd-sp Adr	Sector (Health Care)	Index (Russel 2000)
3 Months	-34.61%	-8.5%	0.0%
6 Months	-40.95%	-4.7%	0.0%
1 Year	-75.94%	0.6%	0.0%
3 Years	-99.8%	6.0%	-15.6%

Redhill Biopharma-sp Adr Key Statistics

in dollars & INR

Previous Close	$5.6931
Open	$5.83
Today's High	$5.83
Today's Low	$5.61
Market Capitalization	$7.2M
Today's Volume	$2.9K
52 Week High	$31.5025
52 Week Low	$5.41
Revenue TTM	$3.7M
EBITDA	$-20.9M
Earnings Per Share (EPS)	$-302.63
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1708.61%

How to invest in Redhill Biopharma-sp Adr from India?

It is very easy for Indian residents to invest directly in Redhill Biopharma-sp Adr from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Redhill Biopharma-sp Adr stock in both Indian Rupees (INR) and US Dollars (USD). Search for Redhill Biopharma-sp Adr or RDHL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Redhill Biopharma-sp Adr or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Redhill Biopharma-sp Adr shares which would translate to 0.154 fractional shares of Redhill Biopharma-sp Adr as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Redhill Biopharma-sp Adr, in just a few clicks!

Returns in Redhill Biopharma-sp Adr for Indian investors in Rupees

Investment Value

₹1,00,000

Redhill Biopharma-sp Adr investment value today

Current value as on today

₹28,305

Returns

₹71,695

(-71.69%)

Returns from Redhill Biopharma-sp Adr Stock

₹75,928 (-75.93%)

Dollar Returns

₹4,233 (+4.23%)

Indian investors sentiment towards Redhill Biopharma-sp Adr

-25%

Period: Oct 19, 2024 to Jan 17, 2025. Change in 30 Days versus previous period

Search volume for Redhill Biopharma-sp Adr on INDmoney from India has reduced in the last 30 days as on Jan 18, 2025. -25% less investors are searching Redhill Biopharma-sp Adr in the last 30 days versus the previous period.

Global Institutional Holdings in Redhill Biopharma-sp Adr

Federation des caisses Desjardins du Quebec
0.31%
Rhumbline Advisers
0.08%
Advisor Group Holdings, Inc.
0.03%
Morgan Stanley - Brokerage Accounts
0.01%

Analyst Recommendation on Redhill Biopharma-sp Adr

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Redhill Biopharma-sp Adr(by analysts ranked 0 to 5 stars)

Based on 7 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Redhill Biopharma-sp Adr

What analysts predicted

Upside of 336779.43%

Target:

$19,000.00

Current:

$5.64

Insights on Redhill Biopharma-sp Adr

Price Movement
In the last 1 month, RDHL stock has moved down by -19.4%
Decreasing Revenue
Revenue is down for the last 5 quarters, 18.34M → 1.79M (in $), with an average decrease of 29.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 2.49M → 761.0K (in $), with an average decrease of 69.4% per quarter
RDHL vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 93.7% return, outperforming this stock by 170.9%
RDHL vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 212.8% return, outperforming this stock by 312.6%
Price to Sales
ForRDHL every $1 of sales, investors are willing to pay $1.2, whereas for Intra-cellular Therapies, Inc., the investors are paying $20.7 for every $1 of sales.

Redhill Biopharma-sp Adr Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$8.4M	↑ 108.63%
Net Income	$-38.8M	↓ 14.76%
Net Profit Margin	-464.35%	↑ 672.26%

	FY19	Y/Y Change
Revenue	$6.3M	↓ 24.75%
Net Income	$-43.6M	↑ 12.4%
Net Profit Margin	-693.59%	↓ 229.24%

	FY20	Y/Y Change
Revenue	$64.4M	↑ 923.03%
Net Income	$-89.0M	↑ 104.01%
Net Profit Margin	-138.31%	↑ 555.28%

	FY21	Y/Y Change
Revenue	$85.8M	↑ 33.25%
Net Income	$-114.3M	↑ 28.41%
Net Profit Margin	-133.3%	↑ 5.01%

	FY22	Y/Y Change
Revenue	$61.8M	↓ 27.94%
Net Income	$-59.2M	↓ 48.17%
Net Profit Margin	-95.87%	↑ 37.43%

	FY23	Y/Y Change
Revenue	$6.5M	↓ 89.46%
Net Income	$23.9M	↓ 140.37%
Net Profit Margin	367.19%	↑ 463.06%

	Q1 FY22	Q/Q Change
Revenue	$18.2M	↓ 17.38%
Net Income	$-21.0M	↓ 13.69%
Net Profit Margin	-115.35%	↓ 4.92%

	Q2 FY22	Q/Q Change
Revenue	$18.3M	↑ 0.6%
Net Income	$-14.3M	↓ 32.2%
Net Profit Margin	-77.74%	↑ 37.61%

	Q3 FY22	Q/Q Change
Revenue	$17.6M	↓ 4.33%
Net Income	$-64.3M	↑ 350.77%
Net Profit Margin	-366.31%	↓ 288.57%

	Q4 FY22	Q/Q Change
Revenue	$12.8M	↓ 27.09%
Net Income	$2.5M	↓ 103.87%
Net Profit Margin	19.46%	↑ 385.77%

	Q1 FY23	Q/Q Change
Revenue	$12.8M	↑ 0.0%
Net Income	$2.5M	↑ 0.0%
Net Profit Margin	19.46%	↑ 0.0%

	Q2 FY23	Q/Q Change
Revenue	$1.8M	↓ 85.97%
Net Income	$761.0K	↓ 69.44%
Net Profit Margin	42.37%	↑ 22.91%

	FY18	Y/Y Change
Profit	$5.5M	↑ 193.62%

	FY19	Y/Y Change
Profit	$4.0M	↓ 27.0%

	FY20	Y/Y Change
Profit	$27.5M	↑ 581.23%

	FY21	Y/Y Change
Profit	$36.4M	↑ 32.34%

	FY22	Y/Y Change
Profit	$28.5M	↓ 21.7%

	FY23	Y/Y Change
Profit	$3.1M	↓ 89.27%

	Q1 FY22	Q/Q Change
Profit	$10.2M	↑ 272.74%

	Q2 FY22	Q/Q Change
Profit	$9.4M	↓ 8.34%

	Q3 FY22	Q/Q Change
Profit	$8.1M	↓ 13.37%

	Q4 FY22	Q/Q Change
Profit	$4.2M	↓ 48.15%

	Q1 FY23	Q/Q Change
Profit	$4.2M	↑ 0.0%

	Q2 FY23	Q/Q Change
Profit	$990.0K	↓ 76.43%

	FY18	Y/Y Change
Operating Cash Flow	$-34.5M	↓ 23.02%
Investing Cash Flow	$5.4M	↓ 128.8%
Financing Cash Flow	$41.8M	↑ 62.8%

	FY19	Y/Y Change
Operating Cash Flow	$-40.7M	↑ 18.24%
Investing Cash Flow	$5.2M	↓ 3.51%
Financing Cash Flow	$35.5M	↓ 14.97%

	FY20	Y/Y Change
Operating Cash Flow	$-48.6M	↑ 19.22%
Investing Cash Flow	$-35.6M	↓ 790.34%
Financing Cash Flow	$84.4M	↑ 137.6%

	FY21	Y/Y Change
Operating Cash Flow	$-65.0M	↑ 33.9%
Investing Cash Flow	$-8.1M	↓ 77.17%
Financing Cash Flow	$73.5M	↓ 12.93%

	Q1 FY22	Q/Q Change
Operating Cash Flow	$-4.2M	↓ 72.04%
Investing Cash Flow	$8.5M	↑ 142.69%
Financing Cash Flow	$-4.9M	↓ 128.14%

	Q2 FY22	Q/Q Change
Operating Cash Flow	$-16.6M	↑ 299.06%
Investing Cash Flow	$-163.0K	↓ 101.92%
Financing Cash Flow	$14.9M	↓ 401.72%

	Q3 FY22	Q/Q Change
Operating Cash Flow	$-6.0M	↓ 63.65%
Investing Cash Flow	$-22.0K	↓ 86.5%
Financing Cash Flow	$-5.7M	↓ 138.35%

Redhill Biopharma-sp Adr Technicals Summary

Sell

Neutral

Buy

Redhill Biopharma-sp Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Redhill Biopharma-sp Adr Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Redhill Biopharma Ltd-sp Adr	-12.88%	-40.95%	-75.94%	-99.8%	-99.91%
Intra-cellular Therapies, Inc.	49.99%	65.01%	92.82%	225.76%	396.26%
Haleon Plc Spon Ads	-4.74%	3.59%	8.83%	24.7%	24.7%
Zoetis Inc.	1.45%	-8.23%	-11.94%	-17.29%	16.88%
Neurocrine Biosciences Inc.	6.15%	-1.39%	4.29%	96.7%	35.64%
Viatris Inc.	-6.84%	-3.17%	-0.88%	-23.23%	-30.84%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Redhill Biopharma Ltd-sp Adr	0.08	NA	0.0	0.0	-17.09	-0.45	NA	0.05
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.7	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	28.72	28.88	1.66	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	31.84	31.84	2.63	5.88	0.47	0.15	0.01	11.59
Neurocrine Biosciences Inc.	37.85	37.9	0.33	6.6	0.16	0.12	NA	26.87
Viatris Inc.	224.4	NA	0.07	2.69	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Redhill Biopharma Ltd-sp Adr	Buy	$7.2M	-99.91%	0.08	0.0%
Intra-cellular Therapies, Inc.	Buy	$13.4B	396.26%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$41.6B	24.7%	28.72	10.75%
Zoetis Inc.	Buy	$76.4B	16.88%	31.84	26.55%
Neurocrine Biosciences Inc.	Buy	$14.4B	35.64%	37.85	17.21%
Viatris Inc.	Hold	$13.5B	-30.84%	224.4	-5.87%

About Redhill Biopharma-sp Adr

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Organization	Redhill Biopharma-sp Adr
Employees	53
CEO	Mr. Dror Ben-Asher
Industry	Health Technology

Management People of Redhill Biopharma-sp Adr

Name	Title
Mr. Dror Ben-Asher	Co-Founder, Chairman & CEO
Mr. Razi Ingber	Chief Financial Officer
Mr. Gilead Raday MPhil, MSc	Chief Operating Officer
Mr. Adi Frish	Chief Corporate & Business Development Officer
Mr. Rick D. Scruggs	Chief Commercial Officer, President of RedHill Biopharma Inc. & Director
Ms. Alexandra Okmian	Senior Business Development & Investor Relations Manager
Dr. Reza Fathi Ph.D.	Senior Vice President of Research & Development
Mr. Guy Goldberg J.D.	Chief Business Officer
Ms. Patricia Anderson B.Sc. RAC	Senior Vice President of Regulatory Affairs

Important FAQs about investing in Redhill Biopharma-sp Adr from India :

What is Redhill Biopharma-sp Adr share price today?

Redhill Biopharma-sp Adr share price today stands at $5.64, Open: $5.83 ; Previous Close: $5.69 ; High: $5.83 ; Low: $5.61 ; 52 Week High: $31.50 ; 52 Week Low: $5.41. The stock opens at $5.83, after a previous close of $5.69. The stock reached a daily high of $5.83 and a low of $5.61, with a 52-week high of $31.50 and a 52-week low of $5.41.

Can Indians buy Redhill Biopharma-sp Adr shares?

Yes, Indians can invest in the Redhill Biopharma-sp Adr (RDHL) from India.

With INDmoney, you can buy Redhill Biopharma-sp Adr at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Redhill Biopharma-sp Adr at zero transaction cost.

How can I buy Redhill Biopharma-sp Adr shares from India?

It is very easy to buy Redhill Biopharma-sp Adr from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Redhill Biopharma-sp Adr be purchased?

Yes, you can buy fractional shares of Redhill Biopharma-sp Adr with INDmoney app.

What are the documents required to start investing in Redhill Biopharma-sp Adr stocks?

To start investing in Redhill Biopharma-sp Adr, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.